Company: CERO
Filing Date: 2025-02-13
Form Type: 424B3
Source: 0001213900-25-013493
Chunk: 1

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-13
Form: 424B3
Chunk 1
---
 reduced public company reporting requirements.

Investing in our securities involves a high degree of risk. Before buying any securities, you should carefully read the discussion of the risks of investing in our securities in “Risk Factors” beginning on page 31 of the Prospectus.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of the securities to be issued under the Prospectus or determined if the Prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

<div align='center'>The date of this Prospectus Supplement is February 13, 2025.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 5, 2025

CERO THERAPEUTICS HOLDINGS, Inc.

(Exact name of registrant as specified in its charter)</div>

| Delaware                     |     | 001-40877               |     | 87-1088814       |
| (State or Other Jurisdiction 
 of Incorporation)            |     | -Commission File Number |     | -I.R.S. Employer 
 Identification   
 No.              |

<div align='center'>201 Haskins Way, Suite 230, South San Francisco, CA 94080

(Address of Principal Executive Offices) (Zip Code)

(650) 407-2376

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)</div>

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

| ☐ | Written                                                                       
 communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |

| ☐ | Soliciting                                                                  
 material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |

| ☐ | Pre-commencement                                                                      
 communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |

| ☐ | Pre-commencement                                                                      
 communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c